Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.

A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...

A new clinical trial from Scripps Research in La Jolla aims to make significant gains in the global fight against malaria by making a drug that has been around since the 1970s last longer. Working ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

In these turblent economic times, your business reputation has never been more important and is in your control. Focusing on your greatest asset will not only safeguard your good name in ...

Pleasant's boys bowling team will try to repeat its Division II state championship on Saturday, while North Union bowler ...

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan ...